Published in AIDS on August 24, 2014
Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis (2015) 1.03
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. BMC Public Health (2015) 0.81
Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. PLoS One (2015) 0.79
Food Insecurity in HIV-Hepatitis C Virus Co-infected Individuals in Canada: The Importance of Co-morbidities. AIDS Behav (2017) 0.76
Hepatitis C Virus Infection in Chronic Kidney Disease. J Am Soc Nephrol (2016) 0.76
Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. BMC Infect Dis (2017) 0.75
The dollars and sense of chronic hepatitis C infection management. Can J Infect Dis Med Microbiol (2015) 0.75
Multiple cause-of-death data among people with AIDS in Italy: a nationwide cross-sectional study. Popul Health Metr (2017) 0.75
Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs. Curr Opin HIV AIDS (2016) 0.75
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin Infect Dis (2016) 0.75
HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study. BMC Infect Dis (2016) 0.75
Impact of hepatitis C status on 20-year mortality of patients with substance use disorders. Addict Sci Clin Pract (2015) 0.75
A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia. PLoS One (2017) 0.75
The diploid genome sequence of an individual human. PLoS Biol (2007) 44.80
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Genome sequence of the dissimilatory metal ion-reducing bacterium Shewanella oneidensis. Nat Biotechnol (2002) 6.96
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A (2002) 5.28
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2008) 4.79
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis (2010) 3.47
The genome sequence of the anaerobic, sulfate-reducing bacterium Desulfovibrio vulgaris Hildenborough. Nat Biotechnol (2004) 3.43
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend (2006) 2.53
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol (2013) 2.48
Access to kidney transplantation among remote- and rural-dwelling patients with kidney failure in the United States. JAMA (2009) 2.26
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis (2012) 2.00
African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J (2005) 1.99
Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS (2006) 1.98
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med (2005) 1.97
Barriers to participating in an HIV vaccine trial: a systematic review. AIDS (2004) 1.97
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol (2006) 1.96
T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PLoS One (2008) 1.91
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis (2009) 1.86
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Police and public health partnerships: evidence from the evaluation of Vancouver's supervised injection facility. Subst Abuse Treat Prev Policy (2008) 1.83
Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. Transplantation (2008) 1.83
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol (2008) 1.79
Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health (2005) 1.73
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
The effect of race and income on living kidney donation in the United States. J Am Soc Nephrol (2013) 1.72
Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2012) 1.71
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy (2010) 1.64
Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ (2006) 1.64
Sexual violence among a cohort of injection drug users. Soc Sci Med (2003) 1.61
Human adrenal glands secrete vitamin C in response to adrenocorticotrophic hormone. Am J Clin Nutr (2007) 1.60
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology (2011) 1.59
Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr (2003) 1.58
Incarceration experiences in a cohort of active injection drug users. Drug Alcohol Rev (2008) 1.57
A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis (2007) 1.56
Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS (2011) 1.55
Infant feeding and growth: can we answer the causal question? Epidemiology (2012) 1.55
Survival among patients with kidney failure in Jalisco, Mexico. J Am Soc Nephrol (2007) 1.53
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug Alcohol Depend (2006) 1.51
Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ (2004) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol (2011) 1.46
Systematic review of strategies to measure HIV-related diarrhea. HIV Clin Trials (2007) 1.45
Crack across Canada: Comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users. Addiction (2006) 1.45
Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. CMAJ (2004) 1.44
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS (2015) 1.44
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int (2014) 1.42
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med (2002) 1.39
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology (2013) 1.38
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Spliced leader-based metatranscriptomic analyses lead to recognition of hidden genomic features in dinoflagellates. Proc Natl Acad Sci U S A (2010) 1.35
HIV/AIDS in African militaries: an ecological analysis. Med Confl Surviv (2008) 1.34
Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS One (2008) 1.31
Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir Ther (2004) 1.30
Accuracy of conventional and marginal structural Cox model estimators: a simulation study. Int J Biostat (2010) 1.30
Users' guides to the medical literature: how to use an article about mortality in a humanitarian emergency. Confl Health (2008) 1.28
Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol (2010) 1.27
Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health (Oxf) (2007) 1.26
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis (2014) 1.25
Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis (2013) 1.25
Traditional African medicine in the treatment of HIV. Lancet Infect Dis (2005) 1.23
Adherence to antiretroviral therapy among a conflict-affected population in Northeastern Uganda: a qualitative study. AIDS (2008) 1.22
Trace elements in hemodialysis patients: a systematic review and meta-analysis. BMC Med (2009) 1.21
Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J Clin Microbiol (2007) 1.20
Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS (2004) 1.20
Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. Am J Drug Alcohol Abuse (2008) 1.18
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther (2005) 1.18
Barriers to participation in HIV drug trials: a systematic review. Lancet Infect Dis (2006) 1.17
Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol (2009) 1.17
Breastfeeding and infant size: evidence of reverse causality. Am J Epidemiol (2011) 1.17
Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. AIDS Patient Care STDS (2003) 1.14
Major families of multiresistant plasmids from geographically and epidemiologically diverse staphylococci. G3 (Bethesda) (2011) 1.14